Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Evaluating the Time to Palliative Care Referrals in Patients With Small-Cell Lung Cancer: A Single-Centre Retrospective Review.

Watson GA, Saunders J, Coate L.

Am J Hosp Palliat Care. 2018 Nov;35(11):1426-1432. doi: 10.1177/1049909118775066. Epub 2018 May 8.

PMID:
29739231
2.

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.

Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, Massutí B, Palmero R, Aix SP, Carcereny E, Früh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Froesch P, Reguart N, Puente J, Coate L, Barlesi F, Rauch D, Thomas M, Camps C, Gómez-Codina J, Majem M, Porta R, Shah R, Hanrahan E, Kammler R, Ruepp B, Rabaglio M, Kassapian M, Karachaliou N, Tam R, Shames DS, Molina-Vila MA, Stahel RA; BELIEF collaborative group.

Lancet Respir Med. 2017 May;5(5):435-444. doi: 10.1016/S2213-2600(17)30129-7. Epub 2017 Apr 10. Erratum in: Lancet Respir Med. 2018 Dec;6(12):e57.

PMID:
28408243
3.

Early adulthood body mass index, cumulative smoking, and esophageal adenocarcinoma survival.

Spreafico A, Coate L, Zhai R, Xu W, Chen ZF, Chen Z, Patel D, Tse B, Brown MC, Heist RS, Dodbiba L, Teichman J, Kulke M, Su L, Eng L, Knox J, Wong R, Darling GE, Christiani DC, Liu G.

Cancer Epidemiol. 2017 Apr;47:28-34. doi: 10.1016/j.canep.2016.11.009. Epub 2017 Jan 12.

PMID:
28088657
4.

Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial.

Peters S, Stahel RA, Dafni U, Ponce Aix S, Massutí B, Gautschi O, Coate L, López Martín A, van Heemst R, Berghmans T, Meldgaard P, Cobo Dols M, Garde Noguera J, Curioni-Fontecedro A, Rauch D, Mark MT, Cuffe S, Biesma B, van Henten AMJ, Juan Vidal Ó, Palmero Sanchez R, Villa Guzmán JC, Collado Martin R, Peralta S, Insa A, Summers Y, Láng I, Horgan A, Ciardiello F, de Hosson S, Pieterman R, Groen HJM, van den Berg PM, Zielinski CC, Chittazhathu Kurian Kuruvilla Y, Gasca-Ruchti A, Kassapian M, Novello S, Torri V, Tsourti Z, Gregorc V, Smit EF; EMPHASIS-lung Collaborative Group.

J Thorac Oncol. 2017 Apr;12(4):752-762. doi: 10.1016/j.jtho.2016.12.017. Epub 2016 Dec 23.

5.

Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer.

O'Callaghan DS, Rexhepaj E, Gately K, Coate L, Delaney D, O'Donnell DM, Kay E, O'Connell F, Gallagher WM, O'Byrne KJ.

Eur Respir J. 2015 Dec;46(6):1762-72. doi: 10.1183/13993003.00176-2014. Epub 2015 Nov 5.

6.

Illness intrusiveness and subjective well-being in patients with glioblastoma.

Edelstein K, Coate L, Massey C, Jewitt NC, Mason WP, Devins GM.

J Neurooncol. 2016 Jan;126(1):127-135. doi: 10.1007/s11060-015-1943-6. Epub 2015 Sep 29.

PMID:
26419780
7.

Economic impact of 21-gene recurrence score testing on early-stage breast cancer in Ireland.

Smyth L, Watson G, Walsh EM, Kelly CM, Keane M, Kennedy MJ, Grogan L, Hennessy BT, O'Reilly S, Coate LE, O'Connor M, Quinn C, Verleger K, Schoeman O, O'Reilly S, Walshe JM.

Breast Cancer Res Treat. 2015 Oct;153(3):573-82. doi: 10.1007/s10549-015-3555-4. Epub 2015 Sep 12.

PMID:
26364296
8.

Neoadjuvant chemoradiation and surgery improves survival outcomes compared with definitive chemoradiation in the treatment of stage IIIA N2 non-small-cell lung cancer.

Darling GE, Li F, Patsios D, Massey C, Wallis AG, Coate L, Keshavjee S, Pierre A, De Perrot M, Yasufuku K, Cypel M, Waddell T.

Eur J Cardiothorac Surg. 2015 Nov;48(5):684-90; discussion 690. doi: 10.1093/ejcts/ezu504. Epub 2015 Jan 6.

PMID:
25567960
9.

Mucoepidermoid carcinoma of lung masquerading as urothelial carcinoma of bladder.

Graham DM, O'Connor KM, Hinchion J, Coate LE, Burke L, Power DG.

Rep Pract Oncol Radiother. 2013 Aug 7;19(1):62-4. doi: 10.1016/j.rpor.2013.07.004. eCollection 2014 Jan.

10.

Glioblastoma treatment in the elderly in the temozolomide therapy era.

Coate L, McNamara MG, Lwin Z, Macfadden D, Al-Zahrani A, Massey C, Menard C, Millar BA, Sahgal A, Laperriere N, Mason WP.

Can J Neurol Sci. 2014 May;41(3):357-62.

PMID:
24718821
11.

Non-small-cell lung cancer: promising advances in treatment.

Quintyne KI, Walsh L, Coate L.

Lancet Respir Med. 2013 Mar;1(1):e13-4. doi: 10.1016/S2213-2600(13)70008-0. Epub 2013 Jan 14. No abstract available.

PMID:
24321810
12.

Elderly patients with advanced NSCLC in phase III clinical trials: are the elderly excluded from practice-changing trials in advanced NSCLC?

Sacher AG, Le LW, Leighl NB, Coate LE.

J Thorac Oncol. 2013 Mar;8(3):366-8. doi: 10.1097/JTO.0b013e31827e2145.

13.

Surgical resection for non-small cell lung cancer: clinical features and outcomes for a consecutive series at an Irish tertiary referral centre.

Al-Alao BS, O'Callaghan DS, Gately K, Nicholson S, Coate LE, O'Connell F, McGovern E, O'Byrne KJ, Young VK.

Ir J Med Sci. 2013 Jun;182(2):217-25. doi: 10.1007/s11845-012-0863-0. Epub 2012 Nov 9.

PMID:
23139062
14.

Maintenance therapy in advanced non-small cell lung cancer: evolution, tolerability and outcomes.

Coate LE, Shepherd FA.

Ther Adv Med Oncol. 2011 May;3(3):139-57. doi: 10.1177/1758834011399306.

15.

Impact and feasibility of a comprehensive geriatric assessment in the oncology setting: a pilot study.

Horgan AM, Leighl NB, Coate L, Liu G, Palepu P, Knox JJ, Perera N, Emami M, Alibhai SM.

Am J Clin Oncol. 2012 Aug;35(4):322-8. doi: 10.1097/COC.0b013e318210f9ce.

PMID:
21422992
16.

How affordable are targeted therapies in non-small cell lung cancer?

Coate LE, Leighl NB.

Curr Treat Options Oncol. 2011 Mar;12(1):1-11. doi: 10.1007/s11864-010-0137-x. Review.

PMID:
21267683
17.

Treatment of the elderly when cure is the goal: the influence of age on treatment selection and efficacy for stage III non-small cell lung cancer.

Coate LE, Massey C, Hope A, Sacher A, Barrett K, Pierre A, Leighl N, Brade A, de Perrot M, Waddell T, Liu G, Feld R, Burkes R, Cho BC, Darling G, Sun A, Keshavjee S, Bezjak A, Shepherd FA.

J Thorac Oncol. 2011 Mar;6(3):537-44. doi: 10.1097/JTO.0b013e31820b8b9b.

18.

Germline genetic variation, cancer outcome, and pharmacogenetics.

Coate L, Cuffe S, Horgan A, Hung RJ, Christiani D, Liu G.

J Clin Oncol. 2010 Sep 10;28(26):4029-37. doi: 10.1200/JCO.2009.27.2336. Epub 2010 Aug 2. Review.

PMID:
20679599
19.

Maintenance therapy in advanced non-small cell lung cancer.

Coate LE, Shepherd FA.

J Thorac Oncol. 2010 May;5(5):723-34. doi: 10.1097/JTO.0b013e3181d86e8b. Review.

20.

Molecular predictive and prognostic markers in non-small-cell lung cancer.

Coate LE, John T, Tsao MS, Shepherd FA.

Lancet Oncol. 2009 Oct;10(10):1001-10. doi: 10.1016/S1470-2045(09)70155-X. Review.

PMID:
19796752
21.

A comparison of whole-body MRI and CT for the staging of lymphoma.

Brennan DD, Gleeson T, Coate LE, Cronin C, Carney D, Eustace SJ.

AJR Am J Roentgenol. 2005 Sep;185(3):711-6.

PMID:
16120924
22.

Paint as another possible source of lead exposure in Saudi Arabia.

al-Saleh I, Coate L.

Bull Environ Contam Toxicol. 1995 Sep;55(3):347-50. No abstract available.

PMID:
8520139
23.

Lead exposure in Saudi Arabia from the use of traditional cosmetics and medical remedies.

Ai-Saleh IA, Coate L.

Environ Geochem Health. 1995 Mar;17(1):29-31. doi: 10.1007/BF00188629.

PMID:
24194037
24.

Onchocerca volvulus: frequency of codon usage.

Unnasch TR, Katholi CR, Coate LM.

Exp Parasitol. 1992 Dec;75(4):457-9. No abstract available.

PMID:
1493878

Supplemental Content

Support Center